Effects of Combining Cocoa and Soy in Type 2 Diabetes

NCT ID: NCT01754662

Last Updated: 2019-07-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diabetes is an increasingly common condition affecting millions of people world wide. The cornerstone of treatment is lifestyle that includes looking at the way how people eat. It is known that food containing compounds called polyphenols can reduce the risk of heart disease risk in people with diabetes. Two foods that are rich sources of polyphenols are cocoa (epicatechins) and soy (isoflavones). Previous studies have shown the benefits of these foods in the diets of people with diabetes. It has also been shown that soy isoflavones and cocoa polyphenols can improve the mood in certain groups of patients.

What is not known is whether there is any extra benefit of combining soy protein and isoflavones with cocoa.

The aim of the study is to look at the modification of cardiovascular risk by soy and/or cocoa in patients with type 2 diabetes, alone or in combination.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. General information about the study

The target number of participants is 100. All participants are patients with type 2 diabetes on diet alone or metformin treatment. Participants will be asked to eat two soy bars daily for 8 weeks. The length of the study is 10 weeks and involves 4 visits at the Diabetes Research Centre in Hull, UK.

The bars will contain:
* soy protein alone, or
* soy protein with additional isoflavones, or
* soy protein with cocoa, or
* soy protein with isoflavones and cocoa, or
* placebo bars without soy protein, isoflavones or cocoa.

The study is randomised (a computer based allocation schema will be used to decide which bars the participant will need to consume). Participants have the same 20% chance to be participant of any of the above groups. The study is placebo-controlled (there is one arm of placebo bars without soy protein, additional isoflavones or cocoa). The study is double-blind (neither the participants or the research team will know which bars they will take).
2. Study-specific procedures

Visit 1 (week 0). Non-fasting visit. Interested participants discuss the study with a member of the study team who will explain each aspect of the study, following which informed consent will be then obtained. Subsequently, blood pressure, weight, height and waist circumference will be measured, medical history and list of medication are recorded, and blood is taken to determine eligibility. A dietitian will explain about eating a normal diet and the foods we would like the participants to avoid during the study. Vegetarian patients may include too much soy in the diet and for this reason they will not be able to take part in the study. All participants will be non smokers.

Visit 2 (week 2)and Visit 4 (week 10). Fasting visits. Fasting blood is taken and the EndoPAT is performed. Weight, height and waist circumference measurement performed. The EndoPAT test takes between 20-30 minutes. The first box of study bars is dispensed during visit 2. Participants need to consume two bars daily. All remaining uneaten bars and empty wrappers will be collected during visit 4.

Visit 3 (week 6). Non-fasting visit. Height, weight, abdominal circumference, blood pressure are measured. Second box of study bars is dispensed.

Participants are asked to complete a one week food diary and a three day hunger questionnaire before the fasting blood tests. The food diary includes mood rating scales to assess the effect of the consumption of the bars on mood. Participants need to complete these prior to Visit 2 and visit 4.

Participants have 24 hours blood pressure measurement prior to Visit 2 and Visit 4.

24 hours urine collection also takes place prior to visit 2 and visit 4.

3\. Optional test incorporated into the study: Body Volume Index measurement Based on participants preference, Body Volume Index measurement is offered as a complementary tool to assess body shape and weight.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Dietary Intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Soy protein with isoflavones and cocoa

Soy protein with isoflavones and cocoa bars. 2 bars daily for 8 weeks.

Group Type EXPERIMENTAL

Soy protein

Intervention Type DIETARY_SUPPLEMENT

2 bars daily for 8 weeks.

Isoflavones

Intervention Type DIETARY_SUPPLEMENT

2 bars daily for 8 weeks.

Cocoa

Intervention Type DIETARY_SUPPLEMENT

2 bars daily for 8 weeks.

Soy protein alone with cocoa

Soy protein alone with cocoa with no isoflavones. 2 bars daily for 8 weeks.

Group Type EXPERIMENTAL

Soy protein

Intervention Type DIETARY_SUPPLEMENT

2 bars daily for 8 weeks.

Cocoa

Intervention Type DIETARY_SUPPLEMENT

2 bars daily for 8 weeks.

Soy protein with soy isoflavones

Soy protein with isoflavones bar. 2 bars daily for 8 weeks.

Group Type EXPERIMENTAL

Soy protein

Intervention Type DIETARY_SUPPLEMENT

2 bars daily for 8 weeks.

Isoflavones

Intervention Type DIETARY_SUPPLEMENT

2 bars daily for 8 weeks.

Soy protein alone

Soy protein alone without soy isoflavone or cocoa polyphenol. 2 bars daily for 8 weeks.

Group Type EXPERIMENTAL

Soy protein

Intervention Type DIETARY_SUPPLEMENT

2 bars daily for 8 weeks.

Placebo

Placebo bar without soy protein, isoflavones or cocoa polyphenols. 2 bars daily for 8 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Soy protein

2 bars daily for 8 weeks.

Intervention Type DIETARY_SUPPLEMENT

Isoflavones

2 bars daily for 8 weeks.

Intervention Type DIETARY_SUPPLEMENT

Cocoa

2 bars daily for 8 weeks.

Intervention Type DIETARY_SUPPLEMENT

Placebo

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with type 2 diabetes controlled by diet or metformin only
* Stable medication history for 3 months prior to screening visit
* Age 45-80

Exclusion Criteria

* Patients with concurrent illness or any medication (especially antibiotics)3 months prior to enrollment that would effect the study results based on investigator's judgement
* Patients not wishing to allow disclosure to their GPs
* Pre-menopausal women or on hormone replacement therapy
* HbA1c \>9% at screening
* Patients with known food allergies
* Smokers
* Vegans and vegetarians
Minimum Eligible Age

45 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Hull

OTHER

Sponsor Role collaborator

Hull University Teaching Hospitals NHS Trust

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephen Atkin

Role: PRINCIPAL_INVESTIGATOR

University of Hull

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Michael White Diabetes Centre

Hull, North Humberside, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Anderson JW, Smith BM, Washnock CS. Cardiovascular and renal benefits of dry bean and soybean intake. Am J Clin Nutr. 1999 Sep;70(3 Suppl):464S-474S. doi: 10.1093/ajcn/70.3.464s.

Reference Type BACKGROUND
PMID: 10479219 (View on PubMed)

Vedavanam K, Srijayanta S, O'Reilly J, Raman A, Wiseman H. Antioxidant action and potential antidiabetic properties of an isoflavonoid-containing soyabean phytochemical extract (SPE). Phytother Res. 1999 Nov;13(7):601-8. doi: 10.1002/(sici)1099-1573(199911)13:73.0.co;2-o.

Reference Type BACKGROUND
PMID: 10548755 (View on PubMed)

Lee DS, Lee SH. Genistein, a soy isoflavone, is a potent alpha-glucosidase inhibitor. FEBS Lett. 2001 Jul 13;501(1):84-6. doi: 10.1016/s0014-5793(01)02631-x.

Reference Type BACKGROUND
PMID: 11457461 (View on PubMed)

Sorenson RL, Brelje TC, Roth C. Effect of tyrosine kinase inhibitors on islets of Langerhans: evidence for tyrosine kinases in the regulation of insulin secretion. Endocrinology. 1994 Apr;134(4):1975-8. doi: 10.1210/endo.134.4.8137766.

Reference Type BACKGROUND
PMID: 8137766 (View on PubMed)

Wagner JD, Cefalu WT, Anthony MS, Litwak KN, Zhang L, Clarkson TB. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. Metabolism. 1997 Jun;46(6):698-705. doi: 10.1016/s0026-0495(97)90016-0.

Reference Type BACKGROUND
PMID: 9186308 (View on PubMed)

Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab. 1999 Oct;84(10):3479-84. doi: 10.1210/jcem.84.10.6067.

Reference Type BACKGROUND
PMID: 10522983 (View on PubMed)

Goodman-Gruen D, Kritz-Silverstein D. Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J Nutr. 2001 Apr;131(4):1202-6. doi: 10.1093/jn/131.4.1202.

Reference Type BACKGROUND
PMID: 11285326 (View on PubMed)

Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care. 2001 Feb;24(2):228-33. doi: 10.2337/diacare.24.2.228.

Reference Type BACKGROUND
PMID: 11213870 (View on PubMed)

Tsai AC, Vinik AI, Lasichak A, Lo GS. Effects of soy polysaccharide on postprandial plasma glucose, insulin, glucagon, pancreatic polypeptide, somatostatin, and triglyceride in obese diabetic patients. Am J Clin Nutr. 1987 Mar;45(3):596-601. doi: 10.1093/ajcn/45.3.596.

Reference Type BACKGROUND
PMID: 2881482 (View on PubMed)

Jayagopal V, Albertazzi P, Kilpatrick ES, Howarth EM, Jennings PE, Hepburn DA, Atkin SL. Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care. 2002 Oct;25(10):1709-14. doi: 10.2337/diacare.25.10.1709.

Reference Type BACKGROUND
PMID: 12351466 (View on PubMed)

Chedraui P, San Miguel G, Hidalgo L, Morocho N, Ross S. Effect of Trifolium pratense-derived isoflavones on the lipid profile of postmenopausal women with increased body mass index. Gynecol Endocrinol. 2008 Nov;24(11):620-4. doi: 10.1080/09513590802288283.

Reference Type BACKGROUND
PMID: 19031218 (View on PubMed)

Scholey AB, French SJ, Morris PJ, Kennedy DO, Milne AL, Haskell CF. Consumption of cocoa flavanols results in acute improvements in mood and cognitive performance during sustained mental effort. J Psychopharmacol. 2010 Oct;24(10):1505-14. doi: 10.1177/0269881109106923. Epub 2009 Nov 26.

Reference Type BACKGROUND
PMID: 19942640 (View on PubMed)

Konya J, Sathyapalan T, Kilpatrick ES, Atkin SL. The Effects of Soy Protein and Cocoa With or Without Isoflavones on Glycemic Control in Type 2 Diabetes. A Double-Blind, Randomized, Placebo-Controlled Study. Front Endocrinol (Lausanne). 2019 May 9;10:296. doi: 10.3389/fendo.2019.00296. eCollection 2019.

Reference Type BACKGROUND
PMID: 31143160 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R1188

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Type 2 Diabetes Haptoglobin Phenotype and Vitamin E
NCT01113671 COMPLETED PHASE2/PHASE3
Cocoa Flavanols and Painfree Walking Distance
NCT01064583 COMPLETED PHASE1/PHASE2
Soy Supplementation and Gestational Diabetes
NCT02806739 COMPLETED EARLY_PHASE1